An Exploratory Clinical Study to Evaluate the Safety, Tolerability, Immune Response and Preliminary Efficacy of LM103 Injection in Combination With PD-1 in Patients With Advanced Solid Tumours

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 23, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

June 30, 2027

Conditions

Solid Cancer

Interventions

BIOLOGICAL

LM103

Patients were treated with PD-1, cyclophosphamide and fludarabine, LM103 and IL-2 treatment.

Trial Locations (1)

RECRUITING

Tianjin Beichen Hospital, China

All Listed Sponsors

lead

Suzhou BlueHorse Therapeutics Co., Ltd.

INDUSTRY